We are live on ! Find out more
AIM icon

AIM ImmunoTech
AIM

15 hedge funds and large institutions have $1.23M invested in AIM ImmunoTech in 2015 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

258% more capital inflows, than outflows

Capital inflows: $122K | Capital outflows: $34.2K

100% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 2

15% more funds holding

Funds holding: 13 → 15 (+2)

0.28% more ownership

Funds ownership: 5.92% → 6.2% (+0.28%)

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

Holders
15
Holders Change
+2
Holders Change %
+15.38%
% of All Funds
0.39%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
1
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$61.2K
2
Citadel Advisors
Citadel Advisors
Florida
+$40.8K
3
BlackRock Fund Advisors
BlackRock Fund Advisors
California
+$6.8K
4
Deutsche Bank
Deutsche Bank
Germany
+$6.8K
5
Two Sigma Securities
Two Sigma Securities
New York
+$6.8K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$13.6K
2
Guggenheim Capital
Guggenheim Capital
Illinois
-$7K
3
Goldman Sachs
Goldman Sachs
New York
-$6.8K
4
Virtu KCG Holdings
Virtu KCG Holdings
New York
-$6.8K

AIM Hedge Fund Activity: Q4 2015 in Review

15 of the 3,824 institutional investors tracked by Wall St. Rank reported a position in AIM ImmunoTech (AIM) for Q4 2015, worth a combined $1.23M — down 50% from $2.49M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new AIM positions and 2 closed out — a net gain of 2 holders — while 1 added to existing stakes and 2 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $61.2K. The largest seller was Vanguard Group, cutting an estimated $13.6K.

  • 15 institutional investors held AIM ImmunoTech (AIM) as of Q4 2015, up from 13 in Q3 2015.
  • Funds reported $1.23M of AIM ImmunoTech stock for Q4 2015, down 50% quarter-over-quarter.
  • 4 funds opened new AIM ImmunoTech positions in Q4 2015 and 2 closed out, a net change of +2 holders.
  • The largest AIM ImmunoTech buyer in Q4 2015 was Renaissance Technologies, an estimated $61.2K added.
  • The largest AIM ImmunoTech seller in Q4 2015 was Vanguard Group, an estimated $13.6K sold.

Based on aggregated 13F filings for Q4 2015.